PARPi维持治疗用于复发性卵巢癌的真实世界应用:中国单中心研究
该单中心回顾性研究评估了中国复发性卵巢癌患者中PARPi维持治疗的实际应用情况。2019至2022年间,铂敏感复发性卵巢癌患者接受PARPi维持治疗的比例逐年增至29.6%、53.3%、43.8%和62.2%。48例患者中位无进展生存期(PFS)为26.1个月(95%CI 20.2-32.1),对初始治疗的反应是PFS的独立预后因素(相对风险3.248,95%CI 1.081-9.757,P=0.036)。
要点
- 2019至2022年铂敏感复发性卵巢癌PARPi维持治疗比例逐年增至29.6%、53.3%、43.8%和62.2%。
- 48例患者中位PFS为26.1个月(95%CI 20.2-32.1)。
- 对初始治疗的反应是PFS的独立预后因素(相对风险3.248,95%CI 1.081-9.757,P=0.036)。
核心结论
- PARPi维持治疗在真实世界应用中同样有效。
- 对初始治疗达到完全缓解(CR)是有利于PFS的独立因素。
- 作者认为,仍应考虑以初次手术达到最佳肿瘤细胞减灭及提高CR率为目标的初始治疗选择,这在新治疗模式下对患者长期预后有积极影响。
研究设计与样本
- 单中心回顾性研究,采用代表性随机对照试验的纳入和排除标准评估本院真实世界临床数据。
- 2019年至2022年间,铂敏感复发性卵巢癌患者接受PARPi维持治疗的比例逐年分析。
- 共48例患者纳入预后分析,其中32例接受奥拉帕利、16例接受尼拉帕利。
主要发现
- 2019至2022年铂敏感复发性卵巢癌患者接受PARPi维持治疗的比例分别为29.6%、53.3%、43.8%和62.2%。
- 采用Study19和SOLO2研究标准,奥拉帕利组符合率分别为56.3%和18.8%。
- 采用NOVA和NORA研究标准,尼拉帕利组符合率分别为31.3%和37.5%。
- 中位PFS为26.1个月(95%CI 20.2-32.1)。
- 对初始治疗的反应是PFS的独立预后因素(相对风险3.248,95%CI 1.081-9.757,P=0.036)。
临床怎么用
- 作者认为,仍应考虑以初次手术达到最佳肿瘤细胞减灭及提高CR率为目标的初始治疗选择,这在新治疗模式下对患者长期预后有积极影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the actual clinical application of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) maintenance therapy in Chinese patients with recurrent ovarian cancer, and to explore prognostic factors associated with progression-free survival (PFS). METHODS: We retrospectively assessed real-world clinical data from our hospital using the inclusion and exclusion criteria of representative randomized controlled trials, analyzed the prognosis, and performed univariate and multivariate analyses of prognostic factors. RESULTS: Between 2019 and 2022, the proportion of platinum-sensitive recurrence ovarian cancer patients who received PARPi maintenance therapy increased to 29.6%, 53.3%, 43.8% and 62.2%, respectively, each year. A total of 48 patients were included in the prognostic analysis, of which 32 and 16 received olaparib and niraparib, respectively. Using the criteria of the Study19 and SOLO2 studies, the olaparib group in our patients had coincidence rates of 56.3% and 18.8%, respectively. Using the criteria of the NOVA and NORA studies, the niraparib group had coincidence rates of 31.3% and 37.5%, respectively. Median PFS was 26.1 months (95% CI 20.2-32.1). Response to primary therapy was an independent prognostic factor for PFS (relative risk, 3.248; 95% CI 1.081-9.757, P = 0.036). CONCLUSIONS: PARPi maintenance therapy was also effective in real world applications. Complete response (CR) to primary therapy was an independent factor favorably affecting PFS. Therefore, primary treatment choices aimed at optimal cytoreduction during primary surgery and improving the CR rate should still be considered, which positively affects the long-term prognosis of patients in the new treatment mode.
引用
- Wang DF, Shi XW, Zhang C, et al. Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China. Gynecol Oncol. 2023. PMID: 36608384. doi:10.1016/j.ygyno.2022.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。